LivaNova PLC — fact timeline

LivaNova PLC shareholders approved Approve share repurchase contracts and authorize entry into repurchase contracts with approved counterparties at the 2026-06-10 meeting.

“6. Ordinary resolution to approve, for the purposes of section 694 of the Companies Act, the terms of the proposed share repurchase contracts set out in Appendix A and Appendix B of the Proxy Statement (the “Share Repurchase Contracts”) and to authorize the Company to enter into a Share Repurchase Contract with any of the Approved Counterparties (as defined in the Proxy Statement)”

LivaNova PLC shareholders approved Disapply pre-emption rights for allotment of shares under section 570 of the Companies Act at the 2026-06-10 meeting.

“Votes For Votes Against Votes Abstained Broker Non-Votes 50,660,968 881,748 122,591 — 6. Ordinary resolution to approve, for the purposes of section 694 of the Companies Act, the terms of the proposed share repurchase contracts set out in Appendix A and Appendix B of the Proxy Statement (the “Share Repurchase Contracts”) and to authorize the Company to enter into a Share Repurchase Contract with any of the Approved Counterparties (as defined in the Proxy Statement) provided that: (A) the maximum aggregate number of Ordinary Shares that may be purchased pursuant to the Share Repurchase Contracts shall not exceed 10% of the total issued Ordinary Shares of the Company as at 5:00 pm Eastern Time on April 13, 2026 as adjusted on a proportionate basis to take into account any consolidation or division of shares from time to time; and (B) (unless previously revoked, varied or renewed by the Com”

LivaNova PLC shareholders approved Authorize directors to allot shares under section 551 of the Companies Act at the 2026-06-10 meeting.

“Votes For Votes Against Votes Abstained Broker Non-Votes 51,098,550 444,170 122,587 — 5. Special resolution subject to the passing of resolution 4 and in accordance with sections 570 and 573 of the Companies Act, to empower the directors generally to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 4, and/or to sell Ordinary Shares (as defined in section 560 of the Companies Act) held by the Company as treasury shares for cash, in each case as if section 561 of the Companies Act (existing shareholders’ pre-emption rights) did not apply to any such allotment or sale, provided that this power is limited to the allotment of equity securities or sale of treasury shares for cash up to an aggregate nominal amount of £10,985,296 , provided that: (A) (unless previously revoked, varied, or renewed by the Company) t”

LivaNova PLC shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 at the 2026-06-10 meeting.

“3. Ordinary resolution to ratify the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership (“PwC-U.S.”), as the Company’s independent registered public accounting firm for 2026. Votes For Votes Against Votes Abstained Broker Non-Votes 51,221,138 414,830 29,339 —”

LivaNova PLC shareholders approved Advisory vote on named executive officer compensation (U.S. Say on Pay) at the 2026-06-10 meeting.

“2. Ordinary resolution to approve, on an advisory basis, the Company’s compensation of its named executive officers (“U.S. Say on Pay”). Votes For Votes Against Votes Abstained Broker Non-Votes 49,311,078 499,536 18,225 1,836,468”

LivaNova PLC shareholders approved Elect Donald Zurbay as director at the 2026-06-10 meeting.

“Mr. Donald Zurbay Votes For Votes Against Votes Abstained Broker Non-Votes 49,714,058 96,890 17,891 1,836,468”

LivaNova PLC shareholders approved Elect Peter Wilver as director at the 2026-06-10 meeting.

“Mr. Peter Wilver Votes For Votes Against Votes Abstained Broker Non-Votes 49,647,347 161,581 19,911 1,836,468”

LivaNova PLC shareholders approved Elect Brooke Story as director at the 2026-06-10 meeting.

“Ms. Brooke Story Votes For Votes Against Votes Abstained Broker Non-Votes 49,349,241 462,872 16,726 1,836,468”

LivaNova PLC shareholders approved Elect Todd Schermerhorn as director at the 2026-06-10 meeting.

“Mr. Todd Schermerhorn Votes For Votes Against Votes Abstained Broker Non-Votes 49,508,349 302,599 17,891 1,836,468”

LivaNova PLC shareholders approved Elect Susan Podlogar as director at the 2026-06-10 meeting.

“Ms. Susan Podlogar Votes For Votes Against Votes Abstained Broker Non-Votes 49,676,374 138,263 14,202 1,836,468”

LivaNova PLC shareholders approved Elect Jette Nygaard-Andersen as director at the 2026-06-10 meeting.

“Ms. Jette Nygaard-Andersen Votes For Votes Against Votes Abstained Broker Non-Votes 49,714,402 97,584 16,853 1,836,468”

LivaNova PLC shareholders approved Elect Vladimir Makatsaria as director at the 2026-06-10 meeting.

“Mr. Vladimir Makatsaria Votes For Votes Against Votes Abstained Broker Non-Votes 49,712,270 102,361 14,208 1,836,468”

LivaNova PLC shareholders approved Elect William A. Kozy as director at the 2026-06-10 meeting.

“Mr. William A. Kozy Votes For Votes Against Votes Abstained Broker Non-Votes 49,471,660 340,680 16,499 1,836,468”

LivaNova PLC shareholders approved Elect Stacy Enxing Seng as director at the 2026-06-10 meeting.

“Ms. Stacy Enxing Seng Votes For Votes Against Votes Abstained Broker Non-Votes 49,343,880 470,546 14,413 1,836,468”

LivaNova PLC shareholders approved Elect Francesco Bianchi as director at the 2026-06-10 meeting.

“Mr. Francesco Bianchi Votes For Votes Against Votes Abstained Broker Non-Votes 49,294,527 517,219 17,093 1,836,468”

LivaNova PLC shareholders approved Elect J. Christopher Barry as director at the 2026-06-10 meeting.

“Mr. J. Christopher Barry Votes For Votes Against Votes Abstained Broker Non-Votes 49,450,193 360,942 17,704 1,836,468”

LivaNova PLC reported the quarter ended March 31, 2026 results: revenue $362.3 million, EPS $0.40. Guidance raised.

“First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period • First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98”

Susan Podlogar was appointed as Director at LivaNova PLC.

“On October 8, 2024, the Board of Directors (the “Board”) of LivaNova PLC (the “Company”) appointed Susan Podlogar to the Board and as a member of the Compensation and Human Capital Management Committee of the Board.”

Trui Hebbelinck departed as Chief Human Resources Officer at LivaNova PLC.

“On September 10, 2024, LivaNova PLC (the “Company”) announced that Trui Hebbelinck, the Company’s Chief Human Resources Officer, will leave her position on September 30, 2024 and commence a period of garden leave.”

LivaNova PLC reported first quarter 2024 results: EPS First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73.

“First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73”

LivaNova PLC reported quarter ended March 31, 2024 results: revenue $294.9 million. Guidance raised.

“quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) • First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS)”

LivaNova PLC incurred convertible notes of $345 million with Citibank, N.A. at 2.50% per year maturing March 15, 2029.

“On March 8, 2024, LivaNova PLC (“LivaNova”) issued $345 million aggregate principal amount of its 2.50% convertible senior notes due 2029 (the “Notes”), including $45 million aggregate principal amount issued pursuant to the exercise in full of the initial purchasers’ option to purchase additional Notes.”

LivaNova PLC entered into Indenture with Citibank, N.A., as trustee valued at $345 million aggregate principal amount (effective 2024-03-08).

“On March 8, 2024, LivaNova PLC (“LivaNova”) issued $345 million aggregate principal amount of its 2.50% convertible senior notes due 2029 (the “Notes”), including $45 million aggregate principal amount issued pursuant to the exercise in full of the initial purchasers’ option to purchase additional Notes. The Notes were issued pursuant to an indenture, dated as of March 8 , 2024 (the “Indenture”), between LivaNova and Citibank, N.A., as trustee.”

LivaNova PLC reported quarter and full year ended December 31, 2023 results: revenue $310.1 million, EPS $0.30. Guidance initiated.

“Financial Summary and Highlights 1 • Fourth-quarter revenue of $310.1 million increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis, as compared to the prior-year period • Fourth-quarter U.S.”

William A. Kozy changed role as Interim Chief Executive Officer at LivaNova PLC.

“William A. Kozy will step down from his current position as Interim Chief Executive Officer of the Company on March 1, 2024 but will remain the Chair of the Board.”

Vladimir A. Makatsaria was appointed as Director at LivaNova PLC.

“In addition, Mr. Makatsaria was appointed as a member of the Board as of the Effective Date.”

Vladimir A. Makatsaria was appointed as Chief Executive Officer at LivaNova PLC.

“the Company’s Board of Directors (the “Board”) appointed Vladimir A. Makatsaria as Chief Executive Officer of the Company, effective as of March 1, 2024”

LivaNova PLC announced a impairment with charges of up to approximately $110 million affecting Advanced Circulatory Support ("ACS") Business Unit.

“the Company expects to incur a pre-tax non-cash impairment charge of up to approximately $110 million in the fourth quarter of 2023”

LivaNova PLC announced a restructuring with charges of $15 million to $20 million affecting Advanced Circulatory Support ("ACS") Business Unit.

“the Company expects to incur pre-tax restructuring charges in the range of approximately $15 million to $20 million.”

LivaNova PLC reported the quarter ended September 30, 2023 results: revenue $286.1 million, EPS $0.73. Guidance raised.

“Third-quarter revenue of $286.1 million increased 13.3% on a reported basis and increased 12.1% on a constant-currency basis, as compared to the prior-year period”

Andrea Saia retired as Director at LivaNova PLC.

“Andrea Saia notified the Company of her decision to retire from the Board, effective December 31, 2023.”

J. Christopher Barry was appointed as Director at LivaNova PLC.

“appointed J. Christopher Barry to the Board and as a member of the Audit and Compliance Committee of the Board.”

Marco Dolci departed as President, Cardiopulmonary Business Unit at LivaNova PLC.

“On September 21, 2023, LivaNova PLC (the “Company”) reported that Marco Dolci, President of the Company’s Cardiopulmonary Business Unit, announced his intent to retire formally from the Company on December 31, 2023 (the “Retirement Date”).”

Marco Dolci departed as President of the Company’s Cardiopulmonary Business Unit at LivaNova PLC.

“On September 21, 2023, LivaNova PLC (the “Company”) reported that Marco Dolci, President of the Company’s Cardiopulmonary Business Unit, announced his intent to retire formally from the Company on December 31, 2023 (the “Retirement Date”).”

LivaNova PLC reported the quarter ended June 30, 2023 results: revenue $293.9 million. Guidance raised.

“technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 • Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and increased 16.4% on a constant-currency basis, as compared to the prior-year period • Second quarter U.S. GAAP diluted earnings per share”

LivaNova PLC shareholders approved Ordinary resolution to authorize the directors.

“10. Ordinary resolution to authorize the directors”

LivaNova PLC shareholders approved Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as UK statutory auditor for 2023.

“Votes For Votes Against Votes Abstained Broker Non-Votes 43,882,990 39,754 14,974 0 10. Ordinary resolution to authorize the directors”

LivaNova PLC shareholders approved Ordinary resolution to receive and adopt the Company’s audited UK statutory accounts at the 2022-12-31 meeting.

“8. Ordinary resolution to receive and adopt the Company’s audited UK statutory accounts for the year ended December 31, 2022, together with the reports of the directors and auditors thereon.”

LivaNova PLC shareholders approved Ordinary resolution to approve, on an advisory basis, the UK directors’ remuneration report at the 2022-12-31 meeting.

“7. Ordinary resolution to approve, on an advisory basis, the United Kingdom (“UK”) directors’ remuneration report in the form set out in the Company’s UK annual report for the period ended December 31, 2022.”

LivaNova PLC shareholders approved Special Resolution to empower directors to allot equity securities for cash without pre-emption rights.

“Votes For Votes Against Votes Abstained Broker Non-Votes 43,107,358 814,021 16,339 0 7. Ordinary resolution to approve, on an advisory basis, the United Kingdom (“UK”) directors’ remuneration report in the form set out in the Company’s UK annual report for the period ended December 31, 2022.”

LivaNova PLC shareholders approved Ordinary resolution to generally and unconditionally authorize the directors to allot shares.

“Votes For Votes Against Votes Abstained Broker Non-Votes 43,540,473 381,719 15,526 0 6. Special Resolution subject to the passing of resolution 5 and in accordance with sections 570 and 573 of the Companies Act, to empower the directors generally to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 5, and/or to sell ordinary shares (as defined in section 560 of the Companies Act) held by the Company as treasury shares for cash, in each case as if section 561 of the Companies Act (existing shareholders’ pre-emption rights) did not apply to any such allotment or sale, provided that this power is limited to the allotment of equity securities or sale of treasury shares for cash up to an aggregate nominal amount of £10,770,848, provided that: (A) (unless previously revoked, varied or renewed by the Company) this”

LivaNova PLC shareholders approved Ordinary resolution to approve the Amended and Restated LivaNova PLC 2022 Incentive Award Plan.

“4. Ordinary resolution to approve the Amended and Restated LivaNova PLC 2022 Incentive Award Plan.”

LivaNova PLC shareholders approved Ordinary resolution to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2023.

“3. Ordinary resolution to ratify the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership ("PwC USA"), as the Company’s independent registered public accounting firm for 2023.”

LivaNova PLC shareholders approved Ordinary resolution to approve, on an advisory basis, the Company’s compensation of its named executive officers ("US Say-on-Pay").

“2. Ordinary resolution to approve, on an advisory basis, the Company’s compensation of its named executive officers (“US Say-on-Pay”).”

LivaNova PLC shareholders approved Election of directors for a term expiring at the AGM to be held in 2024.

“Ordinary resolution to elect, by separate resolutions, each of the following nine (9) directors for a term expiring at the AGM to be held in 2024:”

LivaNova PLC reported the quarter ended March 31, 2023 results: revenue $263.4 million, net income $0.14 per share, EPS $0.14. Guidance raised.

“innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 • First-quarter revenue of $263.4 million increased 9.7 percent on a reported basis and increased 12.7 percent on a constant-currency basis, as compared to the prior-year period • First-quarter U.S. GAAP diluted earnings”

William A. Kozy was appointed as Chief Executive Officer at LivaNova PLC.

“William A. Kozy, Chair of the Company’s Board of Directors (the “Board”), had been appointed interim Chief Executive Officer.”

LivaNova PLC reported first quarter 2023 results: revenue $263 million.

“the company is announcing preliminary first quarter 2023 reported revenue of $263 million, an increase of 9% from first quarter 2022 reported revenue of $240 million”

William A. Kozy was appointed as Chief Executive Officer at LivaNova PLC.

“the Company announced that William A. Kozy, Chair of the Board of Directors, has been appointed interim Chief Executive Officer.”

Damien McDonald resigned as Chief Executive Officer at LivaNova PLC.

“the Company announced that Damien McDonald resigned as Chief Executive Officer of the Company and as a member of the Company’s Board of Directors, effective immediately.”